MedTrace Logo

Effect of Anatabine on Elevated Blood Levels of C-reactive Protein

NCT01607619 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2013-01-28

No results posted yet for this study

Summary

The investigators are studying a dietary supplement called anatabine in a lozenge form named RCP006. The main purpose of this study is to evaluate the effects of this dietary supplement on normal human inflammatory function. The investigators will see this effect in volunteers who have markers of higher levels of inflammation to begin with. The investigators anticipate that anatabine will reduce markers of inflammation. Therefore the investigators are looking for volunteers with high blood levels of C-reactive Protein (CRP) and will monitor the blood CRP levels at several time points throughout the study.

Conditions

Interventions

DIETARY_SUPPLEMENT

Anatabine

1mg anatabine in a mint-flavored mannitol lozenge

Sponsors & Collaborators

  • Roskamp Institute Inc.

    lead OTHER

Principal Investigators

  • Dale Wilson, MD · McLaren Community Medical Center

  • Vittorio Morreale, MD · Medical Practice, Shelby Township

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01607619 on ClinicalTrials.gov